Abstract:Abstract Background Cancer cells are generally under endoplasmic reticulum(ER) stress. Notably, the ability of cells to respond to ER stress is critical for cell survival, and chronic or unresolved ER stress can lead to apoptosis. Glucose-regulated protein (GRP) 78 and C/-EBP homologous protein (CHOP) are commonly used as markers of endoplasmic reticulum (ER) stress. As an ER chaperone, GRP78 functions as a potent anti-apoptotic factor and confers drug resistance, whereas CHOP is a key initiating factor of ER stress-related cell death. The clinical implications of GRP78 and CHOP, however, have not been fully studied in breast cancer. In this study, we aimed to investigate the predictive value of GRP78 and CHOP in breast cancer patients who underwent adjuvant chemotherapy. Methods: An immunohistochemistry screen for GRP78 and CHOP was performed using a tissue microarray (TMA) containing 250 tumors from female patients diagnosed with invasive ductal breast carcinoma at the Fudan University Shanghai Cancer Center. The staining results were scored semi-quantitatively, and a prediction model was constructed to verify the hypothesis. Results: In this retrospective study cohort, positive GRP78 staining was detected in 52.6% (n = 112; 52.6% positive, 47.4% negative) of tumors, and CHOP staining was present in 56.3% (n = 120; 56.3% positive, 43.7% negative) of cases. In Kaplan-Meier analysis, CHOP correlated with prolonged disease-free survival (DFS; P = 0.001), whereas GRP78 showed an opposite association (P < 0.001). Moreover, in a GRP78-positive subset, CHOP overexpression correlated with a lower risk of recurrence. A further multivariate COX analysis revealed that positive GRP78 staining cases exhibited a higher likelihood for disease events (HR = 4.573; 95% CI: 2.291-9.128; P < 0.001), while CHOP positivity was indicative of lower risk for recurrence (HR = 0.385, 95% CI: 0.215-0.688; P = 0.001). In the receiver operating characteristic (ROC) analysis, the prediction capability of the predictive model combining the above two markers surpassed that of a traditional model (P = 0.0085 for the area under the curve comparison). Within the anthracycline-treatment subgroup, the combined GRP78 and CHOP exhibited similar predictive significance. Conclusions: Collectively, our findings suggest a tight association between ER stress markers and clinical outcomes for female patients diagnosed with invasive ductal breast carcinoma. Adding these two ER stress markers to traditional prognostic factors provides a more sensitive and accurate predictive model for female patients with invasive ductal breast cancer. Moreover, the combination of GRP78 and CHOP has predictive value for responsiveness to anthracycline-based adjuvant breast cancer chemotherapy. Thus, our findings provide insights into further applications of GRP78 and CHOP, potentially providing additional predictive information for oncologists with regard to choosing treatment regimens. Citation Format: Yi-Zi Zheng, Zhi-Gang Cao, Xin Hu, Zhi-Ming Shao. Glucose-regulated protein 78 and C/-EBP homologous protein predict disease-free survival and responsiveness to chemotherapy in breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-08-27.

The endoplasmic reticulum stress markers GRP78 and CHOP predict disease-free survival and responsiveness to chemotherapy in breast cancer

Abstract P6-08-27: Glucose-regulated Protein 78 and C/-EBP Homologous Protein Predict Disease-Free Survival and Responsiveness to Chemotherapy in Breast Cancer

FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients

Expression of endoplasmic reticulum chaperone GRP78 in breast cancer and its prognosis significance

Recurrence and Survival Prediction Models for Receiving Preoperative Chemotherapy Pancreatic Ductal Adenocarcinoma Cancer: A Single-center Retrospective Research

GRP78 as a Novel Predictor of Responsiveness to Chemotherapy in Breast Cancer

RETRACTED: Predictive and Prognostic Value of ER-α36 Expression in Breast Cancer Patients Treated with Chemotherapy

Estrogen Receptor-Related Genes As An Important Panel Of Predictors For Breast Cancer Response To Neoadjuvant Chemotherapy

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

An endoplasmic reticulum stress related signature for clinically predicting prognosis of breast cancer patients

Clinicopathological and Prognostic Significance of C/EBP Homologous Protein (CHOP) in Advanced Gastric Cancer

Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients

An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment.

Expression of glucose-regulated protein 78 as prognostic biomarkers for triple-negative breast cancer

Estrogen receptor—positive breast cancer survival prediction and analysis of resistance–related genes introduction

Immunohistochemical GRP78 as a tumor biomarker may predict poor prognosis in patients with non-small cell lung cancers: a retrospective study.

Grb14 as an independent good prognosis factor for breast cancer patients treated with neoadjuvant chemotherapy.

Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis

Roles and Clinical Significances of ATF6, EMC6, and APAF1 in Prognosis of Pancreatic Cancer

A Chemotherapy Response Prediction Model Derived from Tumor-Promoting B and Tregs and Proinflammatory Macrophages in HGSOC

An Integrated Autophagy-Related Gene Signature Predicts Prognosis in Human Endometrial Cancer